|
|
||||||||
Sections of 1 Critical Care Medicine and 3 Infectious Disease, Rush Medical College, Chicago, Illinois 60612; and 2 The Rogosin Institute and Departments of Biochemistry and Surgery, The New York Hospital-Cornell Medical Center, New York, New York 10021
Lipoprotein phospholipid
(PL) plays a major role in neutralization of endotoxin. This study
tested the hypothesis that prophylactic administration of a PL-enriched
emulsion (PRE), which augments PL content of serum lipoproteins and
neutralizes endotoxin in vitro, would preserve cardiovascular function
and improve survival in porcine septic peritonitis. A control group was
compared with low-, mid-, and high-dose treatment groups that received
PRE by primed continuous infusion for 48 h. A fibrin clot
containing live Escherichia coli 0111.B4 was implanted
intraperitoneally 30 min after the priming dose. Survival increased in
a dose-dependent manner and was correlated with serum PL. Infused PL
was associated with high-density lipoprotein in the low-dose group and
all serum lipoproteins at higher doses. Treatment significantly lowered serum endotoxin and tumor necrosis factor (TNF)-
, preserved cardiac output and ejection fraction, and attenuated increases in systemic and
pulmonary vascular resistances. This study demonstrated that augmentation of lipoprotein PL via administration of PRE
improved survival and offered a novel therapeutic approach to sepsis.
serum endotoxin; tumor necrosis factor; cardiac contractility; cardiac output; lipoprotein
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |